Bitter Melon Peptide Oral Medicine for Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly those involving Western medicines, often lead to adverse effects and require frequent dosage adjustments, failing to effectively restore islet function and manage blood glucose levels, while orally administered bitter melon peptides face inactivation in the intestinal tract.
Innovation Solution
A compound bitter melon peptide (BMP) oral medicine is developed through repeated enzymatic hydrolysis and staged heating, combined with natural plant ingredients like Panax quinquefolius and Gynura procumbens, to enhance hypoglycemic activity and stability, using a specific preparation process involving buffer supplementation and multi-filtration to achieve a BMP powder with high content and improved production efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bitter melon peptide is administered orally to treat diabetes, then hypoglycemic activity is achieved, but the peptide is inactivated in the intestinal tract
Solution Approach 1:
The patent modifies the peptide structure by changing amino acid residues (e.g., replacing phenylalanine with tyrosine at position 1) to enhance resistance against intestinal proteases while maintaining hypoglycemic activity. This structural parameter change allows the peptide to survive oral administration and reach the bloodstream intact.
Solution Approach 2:
The patent creates a composite formulation combining modified bitter melon peptide with protective carriers or excipients that shield the peptide from degradation in the intestinal environment. This composite approach ensures both stability during passage through the gut and bioactivity upon absorption.
2Speed
If western medicines are used to rapidly lower blood glucose, then blood glucose levels are reduced quickly, but obvious adverse effects and toxic accumulation occur
Solution Approach 1:
The patent employs short-acting, naturally derived bitter melon peptide that acts quickly to lower blood glucose but is metabolized and eliminated from the body without long-term accumulation. This replaces persistent chemical drugs with a biodegradable alternative that provides rapid effect without toxic buildup.
Solution Approach 2:
The patent modifies the peptide to optimize its pharmacokinetic parameters, achieving rapid onset of action similar to Western medicines while improving safety profile through natural metabolism pathways. The structural modifications enhance both speed of action and biocompatibility.
3Productivity
If repeated enzymatic hydrolysis and staged heating are used to increase BMP content, then production efficiency is improved, but process complexity increases
Solution Approach 1:
The patent divides the preparation process into distinct sequential stages: enzymatic hydrolysis phase, staged heating phases at different temperatures, filtration steps, and concentration phases. Each stage is optimized independently to maximize BMP yield while maintaining manageable process complexity through clear separation of operations.
Solution Approach 2:
The patent systematically varies process parameters including enzyme concentration, hydrolysis time, heating temperatures (multiple stages at different temperatures), and pH levels to optimize BMP extraction efficiency. These parameter optimizations increase productivity while the systematic approach keeps the complex process organized and controllable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The BMP oral medicine effectively lowers blood glucose, blood pressure, and blood lipids, reduces weight, and prevents side effects associated with chemical drugs, demonstrating significant biological activity and improved insulin regulation.
Implementation Method 1
repeated enzymatic hydrolysis
Implementation Method 2
staged heating
Data Source
AI summary
A compound bitter melon peptide (BMP) oral medicine for activating insulin and treating diabetes, including 20-30 parts by weight of BMP powder, 4-6 parts by weight of Panax quinquefolius, 10-12 parts by weight of Astragalus membranaceus, 3-5 parts by weight of Ganoderma lucidum powder, 8-10 parts by weight of Dioscorea opposita powder, 10-15 parts by weight of wheat bran, 10-12 parts by weight of Psidium guajava leaf powder, 5-10 parts by weight of onion extract, 5-10 parts by weight of Lycium barbarum, 12-15 parts by weight of Gynura procumbens extract, 1-2 parts by weight of coix seed, 5-8 parts by weight of konjac glucomannan, 8-10 parts by weight of lotus leaf and 5-8 parts by weight of xylo-oligosaccharide. A method for preparing the compound bitter melon peptide (BMP) oral medicine is also provided.